Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.59 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARD | Q03181 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexadecane SCHEMBL27840691 | 1.00 | GPR84 (0.59) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octane SCHEMBL2717632 | 1.00 | GPR84 (0.59) | GPR84PPARGPPARDPPARAHDAC11 | |
| 3-Methylbutanoic Acid SCHEMBL627178 | 0.97 | GPR84 (0.56) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL15527828 | 0.91 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Decanoic Acid SCHEMBL15528050 | 0.91 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octanoic Acid SCHEMBL15528089 | 0.91 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Undecanoate SCHEMBL15528113 | 0.91 | GPR84 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| 3-Methylbutanoic Acid SCHEMBL28019449 | 0.91 | TSHR (0.54) | GPR84PPARGPPARDPPARAHDAC11 | |
| Hexanoate SCHEMBL7904664 | 0.89 | AKR1B1 (0.70) | GPR84PPARGPPARDPPARAHDAC11 | |
| 3-Methylbutanoic Acid SCHEMBL28831370 | 0.88 | KDM5A (0.50) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915898-B1 | CRYSTAL FORM I OF CLARITHROMYCIN | ABBOTT LAB (US) | 2003-12-03 | — | — | EP | claimed |
| EP-3450431-B1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20220204469-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-11312697-B2 | Process for the production of alpha-tocotrienol and derivatives | PTC THERAPEUTICS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3137461-B1 | METHOD OF PREPARING AN OPTICALLY ACTIVE PDE10 INHIBITOR | OMEROS CORP (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210009560-A1 | CRYSTALLINE FORMS OF MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-01-14 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2019191620-A1 | CRYSTALLINE FORMS OF MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-3137462-B1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PDE10 INHIBITOR | OMEROS CORP (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2362875-B1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | EDISON PHARMACEUTICALS INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20140221674-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8575369-B2 | Process for the production of alpha-tocotrienol and derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120130093-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-8106223-B2 | Process for the production of alpha-tocotrienol and derivatives | EDISON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100105930-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| EP-2142497-A1 | NEW METHODS | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119804-A1 | NEW METHODS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | MERCK & CO., INC. | 2007-09-27 | — | — | US | disclosed |
| US-20050038074-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | GPR84 2132/4885PPARG 1675/4885PPARD 1491/4885 |
| US-20220204469-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | GPR84 2001/4885PPARG 654/4885PPARD 501/4885 |
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | KIF5B, KIF5A, KIF5C | GPR84 3501/4885PPARG 4459/4885PPARD 4237/4885 |
| US-20210009560-A1 | CRYSTALLINE FORMS OF MODULATORS OF CFTR | CFTR, SLC26A4, CLCN2 | GPR84 1563/4885PPARG 266/4885PPARD 378/4885 |
| US-11312697-B2 | Process for the production of alpha-tocotrienol and derivatives | TTPA, LCAT, PCTP | GPR84 2001/4885PPARG 654/4885PPARD 501/4885 |
| US-20140221674-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | GPR84 2001/4885PPARG 654/4885PPARD 501/4885 |
| US-20120130093-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | GPR84 2001/4885PPARG 654/4885PPARD 501/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | GPR84 2132/4885PPARG 1675/4885PPARD 1491/4885 |
| US-20050038074-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | GPR84 3486/4885PPARG 3758/4885PPARD 3886/4885 |
| US-20100105930-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | GPR84 2001/4885PPARG 654/4885PPARD 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.